GLP-1 stands for glucagon-like peptide-1, a satiety hormone the body produces when we eat to help stimulate digestion and ...

The percentage of adult patients with a diagnosis of overweight or obesity increased from 10.4% in 2019 to 15.7% in 2024.

Tirzepatide is now approved for the treatment of obstructive sleep apnea, highlighting the drug class' potential in sleep ...

Compounded GLP-1s are no longer to be sold following the FDA announcement that the shortage of semaglutide and tirzepatide ended.

Explore the evolving landscape of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) for obesity, highlighting access ...

GLP-1 RA use was associated with significant reductions in body weight, BMI, and waist circumference among pediatric patients with obesity. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) ...

Starting Jan. 1, Point32Health, the owner of Harvard Pilgrim Health Care and Tufts Health Plan, will dramatically change how and when it pays for Zepbound— the insurer’ s preferred GLP-1 ...

The nation’s largest Medicaid program could eliminate coverage of GLP-1 drugs for weight loss. A proposed budget published by California Gov. Gavin Newsom would eliminate coverage for GLP-1 drugs for ...

The best. Even though it’s got a lot of chocolate in it, which doesn’t make much sense to me because chocolate’s supposed to be something that’s really been attacked by the GLP-1s.

Survey data suggest that less than half of employers with 500 or more workers cover GLP-1 medications for obesity. For small employers, coverage is less likely. In response to the frequent lack of ...

Reductions in alcohol intake noted in high and low consumers; no significant difference seen in percentage reductions for men and women. (HealthDay News) — Glucagon-like peptide-1 receptor ...